Valsartan's single-pill combination therapy significantly reduces BP in hypertensive patients
Malaysia: Valsartan (Val)-based single-pill combination (SPC) therapies significantly reduced blood pressure (BP) in hypertensive patients, with 57% of patients achieving target BP over a prolonged follow-up period of 1 year, a recent study has shown. The findings were published online in the Malaysian Journal of Medical Sciences (MJMS).
Uncontrolled hypertension can contribute to cardiovascular disease (CVD) leading to heart failure (HF), stroke, coronary artery disease and kidney disease and is an important health issue. Prescribing a single-pill combination therapy provides the benefit of having an additive BP-lowering effect and reduced adverse effects, as individual drugs in the SPEC therapy are within the tolerable dose range. BP control is achieved quickly and this regimen may help lower the pill burden as medications are indicated for chronic use. The usual combinations of two or three antihypertensive medications include renin-angiotensin-aldosterone system (RAAS) blocker with calcium channel blocker (CCB) and RAAS blocker plus CCB coupled with diuretic, respectively.
To summarize, SPC therapies possess a combined BP-lowering effect and may improve compliance with treatment. Ahmad K. M. Yusof, Cardiology Department, Institut Jantung Negara, Kuala Lumpur, Malaysia, and colleagues aimed to provide real-world evidence on the effectiveness of amlodipine/valsartan (Aml/Val) and amlodipine/ valsartan/hydrochlorothiazide (Aml/Val/HCTZ) SPC therapies for achieving blood pressure control in VaREAL study in hypertension patients from 2013 to 2017.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.